Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Siegel, 2012, Cancer statistics 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138

Li, 2013, Genotyping and genomic profiling of non-small cell-lung cancer: implications for current and future therapies, J Clin Oncol, 31, 1039, 10.1200/JCO.2012.45.3753

Leighl, 2012, Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line, Curr Oncol, 19, S52, 10.3747/co.19.1114

Gerber, 2013, Maintenance chemotherapy for advanced non-small cell lung cancer: new life for an old idea, J Clin Oncol, 31, 1009, 10.1200/JCO.2012.43.7459

Stinchcombe, 2009, Current treatments for advanced stage non-small cell lung cancer, Proc Am Thorac Soc, 6, 233, 10.1513/pats.200809-110LC

Shepherd, 2000, A prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J Clin Oncol, 18, 2095, 10.1200/JCO.2000.18.10.2095

Shepherd, 2005, Erlotinib in previously treated non-small-cell lung cancer, N Engl J Med, 353, 123, 10.1056/NEJMoa050753

Hanna, 2004, Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy, J Clin Oncol, 22, 1589, 10.1200/JCO.2004.08.163

Hotta, 2007, Relationship between response and survival in more than 50,000 patients with advanced non-small cell lung cancer treated with systemic chemotherapy in 143 phase III trials, J Thorac Oncol, 2, 402, 10.1097/01.JTO.0000268673.95119.c7

Reck, 2014, Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised trial, Lancet Oncol, 15, 143, 10.1016/S1470-2045(13)70586-2

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Skobe, 1997, Halting angiogenesis suppresses carcinoma cell invasion, Nat Med, 3, 1222, 10.1038/nm1197-1222

Sandler, 2006, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer, N Engl J Med, 355, 2542, 10.1056/NEJMoa061884

Reck, 2010, Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL), Ann Oncol, 21, 1804, 10.1093/annonc/mdq020

Spratlin, 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, J Clin Oncol, 28, 780, 10.1200/JCO.2009.23.7537

Fuchs, 2014, Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial, Lancet, 383, 31, 10.1016/S0140-6736(13)61719-5

Wilke, 2014, J Clin Oncol, 32

Garon, 2012, Clin Lung Cancer, 13, 505, 10.1016/j.cllc.2012.06.007

Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205

Hollen, 1993, Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS), Eur J Cancer, 29, S51, 10.1016/S0959-8049(05)80262-X

1990, EuroQol—a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9

Booth, 2012, Progression-free survival: meaningful or simply measurable?, J Clin Oncol, 30, 1030, 10.1200/JCO.2011.38.7571

Garassino, 2013, Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial, Lancet Oncol, 14, 981, 10.1016/S1470-2045(13)70310-3

Fossella, 2000, Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens, J Clin Oncol, 18, 2354, 10.1200/JCO.2000.18.12.2354

Kim, 2008, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial, Lancet, 372, 1809, 10.1016/S0140-6736(08)61758-4

Di Maio, 2010, Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials, Eur J Cancer, 46, 735, 10.1016/j.ejca.2009.12.013

Ramalingam, 2008, Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599, J Clin Oncol, 26, 60, 10.1200/JCO.2007.13.1144

Mackey J, Ramos M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. San Antonio Breast Cancer Symposium 36th Annual Meeting; San Antonio, TX, USA; Dec 10–14, 2013: abstr 238.

Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol, 22, 2184, 10.1200/JCO.2004.11.022

Sandler, 2009, Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab, J Clin Oncol, 27, 1405, 10.1200/JCO.2008.16.2412

Hainsworth, 2011, BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer, J Thorac Oncol, 6, 109, 10.1097/JTO.0b013e3181f94ad4

Smith, 2010, Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers, Clin Cancer Res, 16, 3548, 10.1158/1078-0432.CCR-09-2797

Crinò, 2014, Therapeutic options targeting angiogenesis in nonsmall cell lung cancer, Eur Respir Rev, 23, 79, 10.1183/09059180.00008913